Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 5,519 Shares

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 5,519 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $246,147.40. Following the completion of the sale, the senior vice president now directly owns 115,494 shares of the company’s stock, valued at $5,151,032.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Paula Green also recently made the following trade(s):

• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Stock Down 0.3 %

NASDAQ:TWST traded down $0.12 on Friday, hitting $45.40. The stock had a trading volume of 638,544 shares, compared to its average volume of 941,083. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90. The business’s fifty day moving average is $43.65 and its 200 day moving average is $45.43. The company has a market cap of $2.66 billion, a PE ratio of -11.92 and a beta of 1.78.

Analyst Ratings Changes

Several research firms have issued reports on TWST. Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird increased their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Barclays dropped their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans bought a new position in Twist Bioscience during the 3rd quarter valued at $43,992,000. Point72 Asset Management L.P. increased its position in Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after buying an additional 613,057 shares during the last quarter. Fred Alger Management LLC grew its position in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares in the last quarter. Victory Capital Management Inc. increased its stake in Twist Bioscience by 4,133.1% in the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after acquiring an additional 300,891 shares during the last quarter. Finally, Farallon Capital Management LLC purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $9,462,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.